Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects

Salim F. Dabaghi, Suraj G. Kamat, John Payne, Gary F. Marks, Robert Roberts, Andrew I. Schafer, Neal Kleiman

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Aspirin interferes with platelet aggregation by inhibiting the metabolism of arachidonic acid to thromboxane A2. Although both high- and low-dose aspirin therapies are effective for secondary prophylaxis in patients with atherosclerotic vascular disease, the acute response to low-dose aspirin therapy is controversial. Eighteen volunteer subjects ingested 81, 162, or 324 mg of aspirin in a longitudinal crossover study design. Initial doses were randomly assigned and dosing intervals were separated by 2 weeks. Platelet aggregation in response to 0.9 mM arachidonic acid was measured at baseline, 15, 30, 60, and 90 minutes after ingestion. Thromboxane B2 production was assayed on simultaneously obtained samples after stimulation with arachidonic acid. The median inhibition of aggregation was 97%, 97%, and 97% 15 minutes after ingestion of 81, 162, and 324 mg, respectively. Four subjects had <20% inhibition 15 minutes after ingesting 81 mg, but all 4 had >90% inhibition after 30 minutes. Thromboxane B2 production declined by >93% in all subjects at each dose. There was no difference between doses in inhibition of thromboxane B2 production.

Original languageEnglish (US)
Pages (from-to)720-723
Number of pages4
JournalThe American Journal of Cardiology
Volume74
Issue number7
DOIs
StatePublished - Oct 1 1994

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects'. Together they form a unique fingerprint.

Cite this